SLFN11 and small cell lung carcinoma: Current research has identified several promising candidates: in NSCLC, a phase III trial of veliparib showed that LP52-positive patients had significantly improved overall survival, suggesting its predictive potential (62, 63); in ED-SCLC, patients with high SLFN11 expression derived greater PFS benefit from veliparib combined with chemotherapy (64).